Life Sciences
atai Life Sciences Presents Phase 1 Study Data on GRX-917
The article atai Life Sciences Presents Phase 1 Study Data on GRX-917 was originally published on Microdose.
Earlier this year, atai Life Science company…
The article atai Life Sciences Presents Phase 1 Study Data on GRX-917 was originally published on Microdose.
Earlier this year, atai Life Science company GABA Therapeutics announced Positive Final Results from Phase 1 trial of GRX-917.
GRX-917 is a deuterated version of etifoxine, an anxiolytic already approved in France, with rapid onset and efficacy comparable to leading benzodiazepines like alprazolam and lorazepam. The drug is being developed with the aim to treat conditions like generalized anxiety disorder (GAD), anxious depression, social anxiety disorder (SAD), panic disorder, and postpartum depression.
According to atai “GRX-917 will offer a differentiated treatment for GAD with fewer side effects—such as sedation, respiratory depression, and withdrawal.”
For more context on this compound and its potential, atai presented data from its trial yesterday at the Society for Biological Psychiatry (SOBP) Annual Meeting.
It’s pretty heavy on the science, but according to atai the data shows GRX-917 was safe and well-tolerated, with sedation comparable to placebo. See the presentation below.
For more on atai, check out A Deeper Look at atai Life Sciences’ Corporate Update
Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…
Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…
Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner
The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….